StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
H.C. Wainwright Reiterates Buy Rating on Pacira Pharmaceuticals (PCRX)
July 1, 2026 6:59 AM
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating and $38.00 price target on Pacira Pharmaceuticals (NASDAQ: PCRX).The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
